The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients

摘要: Background Patients who have failed traditional treatment of chronic urticaria may require trials alternative medications. Safety profiles, continuous laboratory monitoring, and physician comfort are often barriers to treatment. Objectives To evaluate the safety agents used in urticaria. Methods A retrospective chart review electronic medical records from a single-center allergy immunology clinic major academic hospital was conducted. One hundred twenty-six charts patients with treated were reviewed. Results Adverse effects reported 39 73 (53%) on dapsone, 19 47 (40%) sulfasalazine, 15 36 (42%) tacrolimus, 7 45 (16%) hydroxychloroquine, 9 27 (33%) mycophenolate, 6 8 (75%) cyclosporine, 3 24 (4%) omalizumab. Most these adverse mild, did not discontinuation medication, resolved after stopping medication or decreasing dose. Conclusions The use for treatment of angioedema is generally safe when proper clinical monitoring observed.